Academic Journal
Q1Translational Neurodegeneration
About Translational Neurodegeneration
Translational Neurodegeneration is a scholarly journal published by BioMed Central Ltd. SCImago 2025 places it in Q1 with an SJR of 4.992 and an H-index of 77.
Its listed coverage is 2012-2026 and its research categories include Cellular and Molecular Neuroscience (Q1); Cognitive Neuroscience (Q1); Neurology (clinical) (Q1). The 2025 dataset reports 71 documents and 2947 citations across the latest three-year reporting window.
Translational neurodegeneration is a rapidly evolving field of neuroscience that focuses on translating basic research findings into effective clinical therapies for neurodegenerative diseases. With the rising global burden of disorders such as Alzheimer's disease, Parkinson's disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), the need for translational research has never been more critical.
What Is Translational Neurodegeneration?
At its core, translational neurodegeneration bridges the gap between laboratory discoveries and real-world treatments. It involves multidisciplinary approaches that combine molecular biology, genetics, pharmacology, neurology, and clinical science. The goal is to move promising insights from bench to bedside — transforming experimental data into viable diagnostics, therapies, and preventive measures.
Why Is Translational Neurodegeneration Important?
Neurodegenerative diseases are often progressive and incurable. They not only affect millions worldwide but also place immense emotional and financial stress on patients, families, and healthcare systems. Traditional research often progresses slowly from theoretical understanding to practical application. Translational neurodegeneration accelerates this process by focusing on:
-
Early Detection: Developing biomarkers and imaging techniques for early diagnosis.
-
Drug Discovery: Identifying and testing novel compounds to halt or slow disease progression.
-
Gene Therapy and Stem Cells: Innovating treatments that target the root causes of neurodegeneration.
-
Personalized Medicine: Tailoring treatments based on individual genetic and molecular profiles.
Recent Advances in Translational Neurodegeneration
Recent studies have highlighted several breakthroughs in this field. For instance, researchers have identified key misfolded proteins such as beta-amyloid and tau in Alzheimer's disease and alpha-synuclein in Parkinson’s disease. Targeting these proteins with antibody-based therapies or small molecules is showing promising results in clinical trials.
Moreover, stem cell therapies are being explored for regenerating damaged neurons, while CRISPR-based gene editing is being tested for correcting genetic mutations in diseases like Huntington's. These innovations are possible because of translational efforts that turn theoretical models into practical therapies.
Challenges in Translational Research
Despite progress, several challenges persist. Translational neurodegeneration requires extensive funding, collaboration between academia and industry, and robust clinical trial frameworks. Additionally, many therapies that show promise in animal models fail in human trials due to biological differences.
Ethical considerations also play a role, particularly when dealing with gene editing or stem cell technologies. Ensuring patient safety, informed consent, and long-term monitoring is essential.
The Future of Translational Neurodegeneration
Looking ahead, the field is set to benefit from advancements in artificial intelligence, machine learning, and big data analytics. These tools can help identify disease patterns, predict outcomes, and optimize treatment plans. Cross-border collaborations and open-access research platforms are also fostering global progress in understanding and treating neurodegenerative diseases.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Translational neurodegeneration is an emerging and rapidly evolving field in neuroscience that focuses on converting basic research findings into effective clinical treatments for neurodegenerative disorders. This interdisciplinary domain plays a crucial role in addressing diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis (ALS), which currently have no definitive cures. The primary goal of translational neurodegeneration is to bridge the gap between the laboratory bench and the patient’s bedside, ensuring that groundbreaking research benefits real-world clinical practice.
Understanding Translational Neurodegeneration
Neurodegenerative diseases are characterized by progressive loss of structure or function of neurons, often resulting in cognitive decline, motor dysfunction, and emotional disturbances. Despite significant advancements in neuroscience, there remains a substantial lag in converting basic discoveries into actionable therapies. Translational neurodegeneration aims to overcome this barrier by integrating molecular biology, pharmacology, genetics, imaging, and clinical trials into a cohesive strategy for diagnosis, treatment, and prevention.
Importance and Scope of Translational Research
The scope of translational neurodegeneration is vast and multidisciplinary. It includes:
-
Biomarker Discovery: Early detection is critical in neurodegenerative diseases. Translational research helps identify biomarkers in blood, cerebrospinal fluid, or through imaging, facilitating early diagnosis and monitoring disease progression.
-
Drug Development: By understanding disease mechanisms at a cellular and molecular level, researchers can develop targeted therapies. Translational neurodegeneration accelerates the transition from animal models to human clinical trials.
-
Gene Therapy and Precision Medicine: Advancements in genetic engineering and personalized medicine allow treatments tailored to individual genetic profiles. This precision approach is crucial for complex disorders with varied manifestations.
-
Neuroimaging and AI Integration: Modern neuroimaging tools combined with artificial intelligence (AI) help in accurate diagnosis, patient stratification, and treatment response evaluation, contributing to more effective interventions.
-
Rehabilitation and Patient Care: Translational research also focuses on improving the quality of life of patients through innovations in rehabilitation, caregiver support, and assistive technologies.
Challenges in Translational Neurodegeneration
While the potential is vast, there are significant challenges, including:
-
Limited funding and resources for long-term research.
-
Difficulty in replicating laboratory results in clinical settings.
-
Ethical and regulatory hurdles in human trials.
-
Variability in disease progression among individuals.
Overcoming these challenges requires collaboration between academia, pharmaceutical companies, government agencies, and patient advocacy groups.
Future Prospects
The future of translational neurodegeneration looks promising. With growing investment in neuroscience, global collaborations, and technological innovations, the field is poised to revolutionize how we diagnose and treat neurodegenerative diseases. Emerging therapies such as CRISPR gene editing, stem cell therapy, and neuroprotective agents are currently under investigation and may offer hope for millions worldwide.
Conclusion
Recent Research Articles
Latest publications matched automatically by ISSN.
Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer’s disease
Andrea Papait, Francesca Natale, Antonietta Rosa Silini, Ida Nifo Sarrapochiello et al.
2026-09-09 · DOI: 10.1186/s40035-026-00581-1Central nervous system lymphatic network: from the maintenance of brain homeostasis to emerging therapeutic perspectives in neurodegenerative diseases
Shixin Ding, Jiguang Yang, Ze Wang, Ruiliang Bai et al.
2026-09-01 · DOI: 10.1186/s40035-026-00579-9The gut neuroepithelial unit as a neurodegeneration-relevant interface in the gut–brain axis
Siqi Guo, Rui Guo, Qingyu Zhang, Liyuan Fu et al.
2026-09-01 · DOI: 10.1186/s40035-026-00582-0Phase separation in neurodegenerative disorders: a metabolic perspective on protein aggregation and therapeutic targeting
Shujun Peng, Hui Chen, Guowei Yin, Alexei Verkhratsky et al.
2026-08-31 · DOI: 10.1186/s40035-026-00575-zHSPA8 orchestrates SNARE complex assembly to drive extracellular vesicle-mediated spread of p-tau217 in Alzheimer's disease
Bin Xu, Zhen Guo, Jun Chen, Yazhou Xie et al.
2026-08-27 · DOI: 10.1186/s40035-026-00570-4Correction: Neurotrophic factor-α1/carboxypeptidase E regulates critical protein networks to rescue neurodegeneration, defective synaptogenesis and impaired autophagy in Alzheimer’s disease mice
Lan Xiao, Pranav Sharma, Xuyu Yang, Daniel Abebe et al.
2026-08-25 · DOI: 10.1186/s40035-026-00574-0Bridging the gap: neuroinflammation and the dawn of precision medicine in amyotrophic lateral sclerosis
Lu Tang, Dongsheng Fan
2026-08-24 · DOI: 10.1186/s40035-026-00572-2PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications
Jia Dong James Wang, Andrea York Tiang Teo, Bin Xiao, Yinxia Chao et al.
2026-08-18 · DOI: 10.1186/s40035-026-00568-yThe mitophagy-inflammasome axis: a shared pathological hub in Alzheimer’s and Parkinson’s diseases
Wei Long, Mengqin Yuan, Sirui Wang, Xinyue Tan et al.
2026-08-17 · DOI: 10.1186/s40035-026-00578-wCholesterol nose-to-brain delivery as a possible therapeutic strategy in Huntington’s disease
Monica Favagrossa, Alice Passoni, Marta Valenza, Daria Di Prisco et al.
2026-08-04 · DOI: 10.1186/s40035-026-00569-xBrain insulin resistance as a driver of proteinopathy in neurodegeneration: from cell-type-specific mechanisms to targeted therapeutics
Man Xiang, Si-Yu Cao, Xue-Heng Sun, Jing-Wen Hu et al.
2026-08-03 · DOI: 10.1186/s40035-026-00573-1Neuroinflammation in Alzheimer’s and Parkinson’s diseases: pathogenic mechanisms and therapeutic strategies
Qin-qin Wang, Qing-qing Sun, Yong-shun Guo, Shu Yin et al.
2026-07-29 · DOI: 10.1186/s40035-026-00571-3Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer’s disease
Xiaoyu Hu, Ying Yu, Haorui Luo, Jiabing Li et al.
2026-07-29 · DOI: 10.1186/s40035-026-00567-zApplication of the Allen Human Brain Atlas in Alzheimer’s disease and Parkinson’s disease
Yi Xiao, Shichan Wang, Yanbing Hou, Huifang Shang et al.
2026-07-23 · DOI: 10.1186/s40035-026-00566-0Functional analysis of late-onset Alzheimer’s disease risk genes in Caenorhabditis elegans identifies regulators of neuronal aging
Swapnil G. Waghmare, Meera M. Krishna, Emily C. Maccoux, Ariel L. Franitza et al.
2026-07-23 · DOI: 10.1186/s40035-026-00564-2Protein kinase CK2α′ as a dual modulator of neuroimmune signaling and synaptic dysfunction in tauopathy
Angel White, Peter Gavrilyuk, Persephone Gu, Rafael Falcon-Moya et al.
2026-07-09 · DOI: 10.1186/s40035-026-00563-3Plant-derived mitochondria mitigate aging-related neurodegeneration by reprogramming microglial mitochondrial energy metabolism
Yun Teng, Chao Luo, Qingbo Xu, Jingyao Mu et al.
2026-07-08 · DOI: 10.1186/s40035-026-00565-1Lysophagy protects against ANXA11 amyloid fibril toxicity and propagation in FTLD
Honglin Zheng, Haiyang Luo, Yongting Lu, Yapei Yuan et al.
2026-06-28 · DOI: 10.1186/s40035-026-00561-5Metabolic crosstalk in the ageing brain: astrocyte-neuron coupling as a target for homeostatic restoration and therapy
Lihui Qian, Yanting Deng, Meiying Song, Zhouyuan Zhang et al.
2026-06-22 · DOI: 10.1186/s40035-026-00562-4Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson’s disease
Preethi Sheshadri, Maria Alicia Costa-Besada, Alessia Fisher, Szilvia Kiraly et al.
2026-06-17 · DOI: 10.1186/s40035-026-00559-zReviews
Community Reviews
Version History
April 23, 2025 at 8:27 am
April 23, 2025